HRP20201399T1 - Novi modulatori i postupci njihove uporabe - Google Patents
Novi modulatori i postupci njihove uporabe Download PDFInfo
- Publication number
- HRP20201399T1 HRP20201399T1 HRP20201399TT HRP20201399T HRP20201399T1 HR P20201399 T1 HRP20201399 T1 HR P20201399T1 HR P20201399T T HRP20201399T T HR P20201399TT HR P20201399 T HRP20201399 T HR P20201399T HR P20201399 T1 HRP20201399 T1 HR P20201399T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- residues
- variable region
- antibody
- chain variable
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 17
- 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 claims 13
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 claims 10
- 229940127121 immunoconjugate Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102000001708 Protein Isoforms Human genes 0.000 claims 5
- 108010029485 Protein Isoforms Proteins 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 102000049511 human PTK7 Human genes 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 210000005102 tumor initiating cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (19)
1. Kimerno, CDR-kalemljeno, humanizirano ili rekombinantno ljudsko protutijelo, ili njegov fragment koji veže antigen, naznačeno time, da se specifično veže na ljudski PTK7 i pritom obuhvaća varijabilne regije lakog i teškog lanca, pri čemu:
(a) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 24-34 od SEQ ID NO:62 za VL CDR1, ostaci 50-56 od SEQ ID NO:62 za VL CDR2 i ostaci 89-97 od SEQ ID NO:62 za VL CDR3, i
varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 31-35 od SEQ ID NO:63 za VH CDR1, ostaci 50-65 od SEQ ID NO:63 za VH CDR2 i ostaci 95-102 od SEQ ID NO:63 za VH CDR3,
pri čemu je CDR-numeriranje u skladu s Kabat shemom;
(b) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 23-34 od SEQ ID NO:62 za VL CDR1, ostaci 50-56 od SEQ ID NO:62 za VL CDR2 i ostaci 89-97 od SEQ ID NO:62 za VL CDR3, i
varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 26-32 od SEQ ID NO:63 za VH CDR1, ostaci 50-58 od SEQ ID NO:63 za VH
CDR2 i ostaci 95-102 od SEQ ID NO:63 za VH CDR3,
pri čemu je CDR-numeriranje u skladu s Chothia shemom; ili
(c) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-36 od SEQ ID NO:62 za VL CDR1, ostaci 46-55 od SEQ ID NO:62 za VL CDR2 i ostaci 89-96 od SEQ ID NO:62 za VL CDR3, i
varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-35 od SEQ ID NO:63 za VH CDR1, ostaci 47-58 od SEQ ID NO:63 za VH CDR2 i ostaci 93-101 od SEQ ID NO:63 za VH CDR3,
pri čemu je CDR-numeriranje u skladu s MacCallum shemom.
2. Kimerno, CDR-kalemljeno, humanizirano ili rekombinantno ljudsko protutijelo, ili njegov fragment koji veže antigen, naznačeno time, da se specifično veže na ljudski PTK7 i pritom obuhvaća varijabilne regije lakog i teškog lanca, pri čemu:
(a) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 24-34 od SEQ ID NO:64 za VL CDR1, ostaci 50-56 od SEQ ID NO:64 za VL CDR2 i ostaci 89-97 od SEQ ID NO:64 za VL CDR3, i
varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 31-35 od SEQ ID NO:65 za VH CDR1, ostaci 50-65 od SEQ ID NO:65 za VH CDR2 i ostaci 95-102 od SEQ ID NO:65 za VH CDR3,
pri čemu je CDR-numeriranje u skladu s Kabat shemom;
(b) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 23-34 od SEQ ID NO:64 za VL CDR1, ostaci 50-56 od SEQ ID NO:64 za VL CDR2 i ostaci 89-97 od SEQ ID NO:64 za VL CDR3, i
varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 26-32 od SEQ ID NO:65 za VH CDR1, ostaci 50-58 od SEQ ID NO:65 za VH
CDR2 i ostaci 95-102 od SEQ ID NO:65 za VH CDR3,
pri čemu je CDR-numeriranje u skladu s Chothia shemom; ili
(c) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-36 od SEQ ID NO:64 za VL CDR1, ostaci 46-55 od SEQ ID NO:64 za VL CDR2 i ostaci 89-96 od SEQ ID NO:64 za VL CDR3, i
varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-35 od SEQ ID NO:65 za VH CDR1, ostaci 47-58 od SEQ ID NO:65 za VH CDR2 i ostaci 93-101 od SEQ ID NO:65 za VH CDR3,
pri čemu je CDR-numeriranje u skladu s MacCallum shemom.
3. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1 ili 2, naznačeno time, da obuhvaća:
(a) varijabilnu regiju lakog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:62 i varijabilnu regiju teškog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:63; ili
(b) varijabilnu regiju lakog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:64 i varijabilnu regiju teškog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:65.
4. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1, naznačeno time, da obuhvaća varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:62 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:63.
5. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 2, naznačeno time, da obuhvaća varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:64 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:65.
6. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time, da je to neutralizirajuće, iscrpljujuće protutijelo, i/ili je internalizirajuće protutijelo.
7. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time, da se specifično veže na PTK7 izooblik koji je odabran iz skupine koju čine: izooblik a, izooblik b, izooblik c i izooblik d.
8. Konjugat protutijela, naznačen time, da obuhvaća protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, gdje je to protutijelo konjugirano, povezano, ili na neki drugi način udruženo sa citotoksičnim sredstvom.
9. Farmaceutski pripravak, naznačen time, da obuhvaća protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela u skladu s patentnim zahtjevom 8.
10. Nukleinska kiselina, naznačena time, da kodira varijabilnu regiju teškog lanca i/ili varijabilnu regiju lakog lanca protutijela ili njegovog fragmenta koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7.
11. Vektor ili stanica domaćina, naznačeni time, da sadrže nukleinsku kiselinu u skladu s patentnim zahtjevom 10.
12. Stanica, naznačena time, da obuhvaća protutijelo koje se specifično veže na ljudski PTK7, pri čemu stanica obuhvaća jednu ili više nukleinskih kiselina koje kodiraju sljedeće:
(a) varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:62 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:63; ili
(b) varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:64 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:65.
13. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela prema patentnom zahtjevu 8, naznačeni time, da se upotrebljavaju kao farmaceutski proizvod.
14. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time, da se upotrebljava u detektiranju, dijagnosticiranju ili nadgledanju poremećaja koji je povezan s PTK7 kod pojedinca, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, gdje je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
15. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela prema patentnom zahtjevu 8, naznačeni time, da se upotrebljavaju u liječenju poremećaja koji je povezan s PTK7 kod pojedinca, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, dok je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
16. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela prema patentnom zahtjevu 8, naznačeni time, da se upotrebljavaju u smanjivanju frekvencije stanica koje iniciraju tumor kod pojedinca.
17. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time, da se upotrebljava u postupku in vivo za detektiranje, dijagnosticiranje ili nadgledanje poremećaja koji je povezan s PTK7 kod pojedinca, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, gdje je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
18. Postupak in vivo za detektiranje, dijagnosticiranje ili nadgledanje poremećaja koji je povezan s PTK7, naznačen time, da se provodi uporabom protutijela ili njegovog fragmenta koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, gdje je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
19. Protutijelo ili njegov fragment koji veže antigen, za uporabu u skladu s bilo kojim od patentnih zahtjeva 14 do 15 ili 17, ili konjugat protutijela za uporabu u skladu s patentnim zahtjevom 15, ili postupak prema patentnom zahtjevu 18, naznačeni time, da poremećaj koji je povezan s PTK7 je rak.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161444614P | 2011-02-18 | 2011-02-18 | |
PCT/US2011/050451 WO2012031280A2 (en) | 2010-09-03 | 2011-09-02 | Identification and enrichment of cell subpopulations |
PCT/US2012/025726 WO2012112943A1 (en) | 2011-02-18 | 2012-02-17 | Novel modulators and methods of use |
EP12705776.8A EP2675827B1 (en) | 2011-02-18 | 2012-02-17 | Novel modulators and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201399T1 true HRP20201399T1 (hr) | 2020-11-27 |
Family
ID=46672972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201399TT HRP20201399T1 (hr) | 2011-02-18 | 2020-09-02 | Novi modulatori i postupci njihove uporabe |
Country Status (31)
Country | Link |
---|---|
US (3) | US9409995B2 (hr) |
EP (2) | EP3763388A1 (hr) |
JP (2) | JP6296796B2 (hr) |
KR (1) | KR102022734B1 (hr) |
CN (2) | CN103547597B (hr) |
AR (1) | AR085281A1 (hr) |
AU (3) | AU2012219313C1 (hr) |
BR (1) | BR112013021134B1 (hr) |
CA (1) | CA2827637C (hr) |
CO (1) | CO6791571A2 (hr) |
CY (1) | CY1123551T1 (hr) |
DK (1) | DK2675827T3 (hr) |
ES (1) | ES2829206T3 (hr) |
HR (1) | HRP20201399T1 (hr) |
HU (1) | HUE050657T2 (hr) |
IL (3) | IL228018A (hr) |
LT (1) | LT2675827T (hr) |
MX (1) | MX356434B (hr) |
MY (1) | MY173880A (hr) |
PE (2) | PE20141028A1 (hr) |
PH (1) | PH12018500452A1 (hr) |
PL (1) | PL2675827T3 (hr) |
PT (1) | PT2675827T (hr) |
RS (1) | RS60841B1 (hr) |
RU (2) | RU2627176C2 (hr) |
SA (1) | SA112330278B1 (hr) |
SG (2) | SG192816A1 (hr) |
SI (1) | SI2675827T1 (hr) |
TW (2) | TWI696635B (hr) |
WO (1) | WO2012112943A1 (hr) |
ZA (1) | ZA201306958B (hr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130061340A1 (en) * | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
CA2809864A1 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
SA112330278B1 (ar) * | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
US10323081B2 (en) * | 2011-07-06 | 2019-06-18 | Genmag A/S | Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains |
US9574013B2 (en) | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
CA2907429A1 (en) * | 2013-07-04 | 2015-01-08 | Rheinisch-Westfaelische Technische Hochschule Aachen | A new fusion protein to target and treat acute myloid leukemia cells |
WO2015157976A1 (zh) * | 2014-04-17 | 2015-10-22 | 深圳迈瑞生物医疗电子股份有限公司 | 细胞分析方法和系统、装置 |
BR112016025291A2 (pt) | 2014-04-30 | 2017-12-26 | Abbvie Stemcentrx Llc | conjugados de anticorpo anti-ptk7-fármaco |
AU2018237300A1 (en) | 2017-03-23 | 2019-10-17 | The Trustees Of The University Of Pennsylvania | Anti-C5a antibodies and uses thereof |
US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
BR112020016859A2 (pt) | 2018-02-28 | 2020-12-29 | Pfizer Inc. | Variantes de il-15 e usos da mesma |
BR112020022595A2 (pt) | 2018-05-23 | 2021-02-09 | Pfizer Inc. | anticorpos específicos para gucy2c e usos dos mesmos |
BR112020022897A2 (pt) | 2018-05-23 | 2021-02-23 | Pfizer Inc. | anticorpos específicos para cd3 e usos dos mesmos |
WO2020014175A1 (en) * | 2018-07-10 | 2020-01-16 | Children's Medical Center Corporation | Methods and compositions for analyzing immortalized megakaryocyte progenitor cell lines and platelet-like particles derived therefrom |
JP2022509017A (ja) | 2018-11-07 | 2022-01-20 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 抗ptk7免疫細胞癌療法 |
US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
JP2023506262A (ja) * | 2019-12-16 | 2023-02-15 | 2セブンティ バイオ インコーポレイテッド | 抗bcma car抗体、コンジュゲートおよび使用方法 |
EP4077387A1 (en) | 2019-12-17 | 2022-10-26 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
AU2020410418A1 (en) | 2019-12-18 | 2022-06-09 | Pfizer Inc. | Once daily cancer treatment regimen with a PRMT5 inhibitor |
WO2021181233A2 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
MX2022014180A (es) | 2020-05-13 | 2022-12-02 | Pfizer | Metodos, terapias y usos para tratar cancer. |
KR102678735B1 (ko) * | 2020-07-16 | 2024-06-26 | 연세대학교 산학협력단 | Ptk7에 특이적으로 결합하는 항체 및 이의 용도 |
MX2023000662A (es) | 2020-07-17 | 2023-02-27 | Pfizer | Anticuerpos terapeuticos y sus usos. |
WO2022053990A1 (en) | 2020-09-14 | 2022-03-17 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
CN115894696A (zh) * | 2021-08-18 | 2023-04-04 | 和迈生物科技有限公司 | 抗ptk7单域抗体及其应用 |
WO2023108101A1 (en) * | 2021-12-09 | 2023-06-15 | Emory University | Antibodies that inhibit glycoprotein ib-ix mediated platelet signaling and uses in managing bleeding conditions |
WO2023218320A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
WO2023242769A1 (en) | 2022-06-17 | 2023-12-21 | Pfizer Inc. | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
WO2024009191A1 (en) | 2022-07-05 | 2024-01-11 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
WO2024074977A1 (en) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
WO2024080325A1 (ja) * | 2022-10-14 | 2024-04-18 | Jsr株式会社 | 抗体及びその使用 |
WO2024084364A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the treatment of cancer |
WO2024105563A1 (en) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4265551A (en) | 1977-07-13 | 1981-05-05 | U.S. Philips Corporation | Drive for transporting and reversing an ink ribbon, and for withdrawing the printing head in printing devices |
US4111824A (en) | 1977-07-21 | 1978-09-05 | Gulf Research & Development Co. | Liquid dielectric composition based on a fraction derived from the alkylation product of benzene with ethylene |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
ATE204902T1 (de) | 1990-06-29 | 2001-09-15 | Large Scale Biology Corp | Melaninproduktion durch transformierte mikroorganismen |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
EP0517895B1 (en) | 1990-12-14 | 1996-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
DK0804070T3 (da) | 1993-03-09 | 2000-08-07 | Genzyme Corp | Fremgangsmåde til isolering af proteiner fra mælk |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
NZ292124A (en) | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
KR20010031713A (ko) | 1997-11-03 | 2001-04-16 | 벤슨 로버트 에이치. | 맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제 |
JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
EP1276756A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
EP2314686B2 (en) | 2000-10-06 | 2023-06-21 | Kyowa Kirin Co., Ltd. | Cells producing antibody compositions |
US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
JP2005533001A (ja) | 2002-03-04 | 2005-11-04 | メディミューン,インコーポレーテッド | インテグリンαvβ3アンタゴニストを他の物質と併用投与する癌の予防または治療方法 |
GB0219776D0 (en) * | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
EP1553963A4 (en) | 2002-09-24 | 2006-05-03 | Burnham Inst | NOVEL AGENTS MODULATING EPH RECEPTOR ACTIVITY |
EP2345671B8 (en) | 2002-09-27 | 2023-01-11 | Xencor, Inc. | Optimized fc variants and methods for their generation |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
US7619068B2 (en) | 2003-05-09 | 2009-11-17 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
RU2366716C2 (ru) * | 2003-10-24 | 2009-09-10 | Эсбатек Аг | Способ идентификации и/или проверки ингибиторов рецепторных тирозинкиназ |
CA2574881C (en) | 2004-08-04 | 2013-01-08 | Amgen Inc. | Antibodies to dkk-1 |
AU2005277567A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
US8222253B2 (en) | 2004-10-23 | 2012-07-17 | Case Western Reserve University | Peptide and small molecule agonists of EphA and their uses |
JP2009506790A (ja) | 2005-09-07 | 2009-02-19 | メディミューン,エルエルシー | 毒素とコンジュゲートしたeph受容体抗体 |
US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
SG177194A1 (en) | 2005-12-08 | 2012-01-30 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
EP1973574B1 (en) | 2005-12-30 | 2014-04-02 | Institut Gustave Roussy | Use of inhibitors of scinderin and/or of ephrin-a1 for treating tumors |
US8343461B2 (en) | 2006-03-08 | 2013-01-01 | Wake Forest University Health Sciences | Molecular signature of cancer |
AU2007227292B2 (en) | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
MX2008015492A (es) | 2006-06-06 | 2009-02-12 | Univ Tennessee Res Foundation | Composiciones enriquecidas en celulas madre neoplasicas y metodos que las contienen. |
SI3207941T1 (sl) | 2006-09-07 | 2020-08-31 | Scott & White Memorial Hospital | Postopki in sestavki na osnovi konjugatov toksina davice-interlevkin-3 |
US8309354B2 (en) | 2007-01-22 | 2012-11-13 | Macrogenics West, Inc. | Human cancer stem cells |
WO2008149803A1 (ja) | 2007-06-06 | 2008-12-11 | The University Of Tokyo | 表面抗原マーカーを用いた急性リンパ性白血病における癌幹細胞の分離同定方法 |
WO2009012357A2 (en) | 2007-07-17 | 2009-01-22 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
JP2010538012A (ja) | 2007-08-28 | 2010-12-09 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | Igf−1rの複数のエピトープに結合する組成物 |
WO2009043051A2 (en) | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
WO2009070767A2 (en) * | 2007-11-28 | 2009-06-04 | Whitehead Institute For Biomedical Research | Systemic instigation systems to study tumor growth or metastasis |
MX2010005966A (es) * | 2007-11-30 | 2010-06-15 | Bristol Myers Squibb Co | Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7). |
KR101123130B1 (ko) | 2008-03-17 | 2012-03-30 | 연세대학교 산학협력단 | Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제 |
US8384551B2 (en) | 2008-05-28 | 2013-02-26 | MedHab, LLC | Sensor device and method for monitoring physical stresses placed on a user |
US8197809B2 (en) | 2008-06-25 | 2012-06-12 | Korea Research Institute Of Bioscience And Biotechnology | CD9-specific human antibodies |
WO2010037134A2 (en) | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
US20120003235A1 (en) * | 2008-12-31 | 2012-01-05 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
WO2010081171A2 (en) | 2009-01-12 | 2010-07-15 | Cyntellect, Inc. | Laser mediated sectioning and transfer of cell colonies |
US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
FR2964148A1 (fr) | 2010-08-30 | 2012-03-02 | Peugeot Citroen Automobiles Sa | Boite de degazage destinee au circuit de refroidissement d'un moteur thermique de vehicule automobile |
WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
CA2809864A1 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
EP2446895A1 (en) | 2010-10-01 | 2012-05-02 | Stemgen S.P.A. | EPH receptor expression in tumor stem cells |
SA112330278B1 (ar) * | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
SG11201601424PA (en) | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions |
BR112016025291A2 (pt) * | 2014-04-30 | 2017-12-26 | Abbvie Stemcentrx Llc | conjugados de anticorpo anti-ptk7-fármaco |
US20190209704A1 (en) | 2014-10-20 | 2019-07-11 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions and methods of use |
US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2012
- 2012-02-15 SA SA112330278A patent/SA112330278B1/ar unknown
- 2012-02-17 ES ES12705776T patent/ES2829206T3/es active Active
- 2012-02-17 TW TW106111590A patent/TWI696635B/zh active
- 2012-02-17 AR ARP120100548A patent/AR085281A1/es active IP Right Grant
- 2012-02-17 PL PL12705776T patent/PL2675827T3/pl unknown
- 2012-02-17 PE PE2013001935A patent/PE20141028A1/es active IP Right Grant
- 2012-02-17 RS RS20201138A patent/RS60841B1/sr unknown
- 2012-02-17 PT PT127057768T patent/PT2675827T/pt unknown
- 2012-02-17 AU AU2012219313A patent/AU2012219313C1/en active Active
- 2012-02-17 RU RU2013141976A patent/RU2627176C2/ru active
- 2012-02-17 BR BR112013021134-2A patent/BR112013021134B1/pt active IP Right Grant
- 2012-02-17 CN CN201280019016.6A patent/CN103547597B/zh active Active
- 2012-02-17 EP EP20178593.8A patent/EP3763388A1/en active Pending
- 2012-02-17 US US14/000,289 patent/US9409995B2/en active Active
- 2012-02-17 MX MX2013009541A patent/MX356434B/es active IP Right Grant
- 2012-02-17 RU RU2017126476A patent/RU2017126476A/ru not_active Application Discontinuation
- 2012-02-17 TW TW101105374A patent/TWI624476B/zh active
- 2012-02-17 EP EP12705776.8A patent/EP2675827B1/en active Active
- 2012-02-17 HU HUE12705776A patent/HUE050657T2/hu unknown
- 2012-02-17 LT LTEP12705776.8T patent/LT2675827T/lt unknown
- 2012-02-17 SG SG2013062419A patent/SG192816A1/en unknown
- 2012-02-17 DK DK12705776.8T patent/DK2675827T3/da active
- 2012-02-17 JP JP2013554656A patent/JP6296796B2/ja active Active
- 2012-02-17 PE PE2018001014A patent/PE20181076A1/es unknown
- 2012-02-17 KR KR1020137024803A patent/KR102022734B1/ko active IP Right Grant
- 2012-02-17 CA CA2827637A patent/CA2827637C/en active Active
- 2012-02-17 SG SG10201603926SA patent/SG10201603926SA/en unknown
- 2012-02-17 WO PCT/US2012/025726 patent/WO2012112943A1/en active Application Filing
- 2012-02-17 SI SI201231850T patent/SI2675827T1/sl unknown
- 2012-02-17 CN CN201710094360.6A patent/CN107056945A/zh active Pending
- 2012-02-17 MY MYPI2013701438A patent/MY173880A/en unknown
-
2013
- 2013-08-18 IL IL228018A patent/IL228018A/en active IP Right Grant
- 2013-09-12 CO CO13216897A patent/CO6791571A2/es unknown
- 2013-09-16 ZA ZA2013/06958A patent/ZA201306958B/en unknown
-
2016
- 2016-03-30 US US15/085,223 patent/US9914784B2/en active Active
-
2017
- 2017-05-02 AU AU2017202934A patent/AU2017202934A1/en not_active Abandoned
- 2017-08-20 IL IL254062A patent/IL254062B/en active IP Right Grant
- 2017-11-21 JP JP2017223676A patent/JP2018104409A/ja active Pending
-
2018
- 2018-01-29 US US15/882,391 patent/US10836831B2/en active Active
- 2018-03-01 PH PH12018500452A patent/PH12018500452A1/en unknown
- 2018-11-14 IL IL263020A patent/IL263020A/en unknown
-
2019
- 2019-02-22 AU AU2019201258A patent/AU2019201258A1/en not_active Abandoned
-
2020
- 2020-09-02 HR HRP20201399TT patent/HRP20201399T1/hr unknown
- 2020-11-05 CY CY20201101046T patent/CY1123551T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201399T1 (hr) | Novi modulatori i postupci njihove uporabe | |
HRP20191169T1 (hr) | Konjugati antidll3-protutijelo-pbd i njihove uporabe | |
RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
RU2019118359A (ru) | Антитело к cd73 человека | |
JP2014511179A5 (hr) | ||
JP2016531915A5 (hr) | ||
JP2018127469A5 (hr) | ||
IL295230A (en) | Combination therapy with anti-cd73 antibodies | |
JP2017500028A5 (hr) | ||
JP2017052784A5 (hr) | ||
HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
JP2016513664A5 (hr) | ||
RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
JP2016536020A5 (hr) | ||
JP2018500014A5 (hr) | ||
JP2017535257A5 (hr) | ||
RU2014138041A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
JP2016538318A5 (hr) | ||
NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
AU2018348429A1 (en) | Multispecific antibody | |
RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
JP2011509245A5 (hr) | ||
RU2010126078A (ru) | Антитело против nr10 и его применение |